The global biosimilar monoclonal antibody market size is predicted to increase from USD 13 billion in 2024, grew to USD 16.01 billion in 2025 and is anticipated to reach around USD 104.71 billion by 2034, poised to grow at a CAGR of 23.20% between 2024 and 2034. The North America biosimilar monoclonal antibody market size is calculated at USD 4.55 billion in 2024 and is estimated to grow at a fastest CAGR of 23.37% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Biosimilar Monoclonal Antibody Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Type, 2024-2034
8.1.1 Adalimumab
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Bevacizumab
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Infliximab
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Rituximab
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Trastuzumab
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
8.1.6. Others
8.1.6.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Indication, 2024-2034
9.1.1. Oncology
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Autoimmune diseases
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by End User, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Cancer treatment centers
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by End User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Indication (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by End User (2021-2034)
12.1. Roche
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pfizer
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Samsung Bioepis
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Amgen
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Mylan
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Teva Pharmaceutical Industries
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Biogen
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Celltrion
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Fresenius Kabi
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample